Esperion Therapeutics, Inc.

ESPR

US29664W1053

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:01 2024-04-23 pm EDT			5-day change	1st Jan Change
2.08 ^USD	+8.90%		+8.90%	-30.43%

Mar. 25	Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	DJ
Mar. 25	Sector Update: Health Care Stocks Steady Premarket Monday	MT

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021

January 11, 2022 at 08:00 am EST

Esperion Therapeutics, Inc. provided earnings guidance for the fourth quarter of 2021. For the fourth quarter of 2021 net U.S. product sales are expected to be between $12.0 to $12.5 million.

Latest news about Esperion Therapeutics, Inc.

Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	Mar. 25	DJ
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 25	MT
Transcript : Esperion Therapeutics, Inc. - Special Call	Mar. 25
Top Premarket Gainers	Mar. 25	MT
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	Mar. 22	CI
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	Mar. 22	MT
Esperion Says FDA Approves New Labels for Nexletol and Nexlizet	Mar. 22	DJ
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	Mar. 22	MT
Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications	Mar. 22	DJ
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination	Mar. 22	CI
Transcript : Esperion Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
North American Morning Briefing : Stock Futures -2-	Feb. 27	DJ
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q4 Revenue $32.3M, vs. Street Est of $28.7M	Feb. 27	MT
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	Jan. 19	MT
US Futures Trend Higher as Investors Await Consumer Sentiment, Home Sales Data	Jan. 19	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Tech Stocks Gains	Jan. 19	MT
Top Premarket Decliners	Jan. 19	MT
Esperion Therapeutics Prices $85.1 Million Share Offering	Jan. 19	MT
Esperion Therapeutics Launches Share Offering	Jan. 18	MT
Transcript : Esperion Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM	Jan. 10
Top Midday Decliners	Jan. 03	MT
Esperion Therapeutics, Daiichi Sankyo Europe Settle Commercial Dispute With $125 Million Amendment in Collaboration	Jan. 03	MT
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation	Jan. 03	CI

Chart Esperion Therapeutics, Inc.

Duration

Period

More charts

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Esperion Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.91 USD

Average target price

7.414 USD

Spread / Average Target

+288.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ESPERION THERAPEUTICS, INC.	-30.43%	362M
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals